Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026
Same author

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same author

Targeted microbubble cavitation has no therapeutic effect on atherosclerotic plaques of the aorta in diabetic ApoE<sup>-/-</sup> mice.

Ultrasound in medicine & biology·2026
Same author

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Clinical and translational science·2026
Same author

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Aug 9, 2025

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

658

Systematic study of tissue factor expression in solid tumors.

Johann S de Bono1, Jeffrey R Harris2, Saskia M Burm3

  • 1The Institute of Cancer Research, Royal Cancer Hospital, London, UK.

Cancer Reports (Hoboken, N.J.)
|February 22, 2023
PubMed
Summary
This summary is machine-generated.

Tissue factor (TF) is widely expressed in various solid tumors, including pancreatic and lung cancers. This expression is present during tumor spread and treatment, indicating its role in cancer progression.

Keywords:
biopsies expressionimmunohistochemistrysolid tumortargeted therapytissue factor

More Related Videos

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

876
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.6K

Related Experiment Videos

Last Updated: Aug 9, 2025

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

658
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

876
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.6K

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunohistochemistry

Background:

  • Tissue factor (TF) expression is elevated in many solid cancers and linked to poor prognosis.
  • Previous studies have not systematically compared TF expression across diverse solid tumor types in a single study.

Purpose of the Study:

  • To systematically analyze the prevalence and cellular localization of TF expression in a wide range of solid cancers.
  • To investigate the spatial and temporal variations of TF expression during disease progression and metastasis.

Main Methods:

  • Immunohistochemistry (IHC) using a TF-specific antibody.
  • Analysis of tumor tissue from patients with ovarian, esophageal, bladder, cervical, endometrial, pancreatic, prostate, colon, breast, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and glioblastoma.
  • Comparison of TF expression in primary tumors versus metastatic lesions and across different time points.

Main Results:

  • TF was expressed in all tested cancer types, with the highest prevalence in pancreatic, cervical, colon, glioblastoma, HNSCC, and NSCLC.
  • TF staining patterns varied, being predominantly membranous in some cancers (e.g., pancreatic) and cytoplasmic in others (e.g., glioblastoma).
  • TF expression remained relatively consistent over time and between primary tumors and metastases, though individual patient variability was noted.

Conclusions:

  • TF is broadly expressed across solid tumors.
  • TF expression is maintained during tumor dissemination and treatment.
  • TF represents a potential target for cancer therapy across multiple solid tumor types.